COMPASS Pathways plc
COMP360
treatment-resistant depression (TRD)
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on COMP360 for treatment-resistant depression (TRD) is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 15h ago
“The final NDA submission remains on track for Q4, aligned with the Company’s previously defined accelerated timing.”